Search

Your search keyword '"Marks, David I."' showing total 973 results
Start Over Author "Marks, David I."
973 results on '"Marks, David I."'

1. Acute Lymphoblastic Leukemia in Adults

Author

Stelljes, Matthias, Marks, David I., Giebel, Sebastian, Sureda, Anna, editor, Corbacioglu, Selim, editor, Greco, Raffaella, editor, Kröger, Nicolaus, editor, and Carreras, Enric, editor

Published
2024
Full Text
View/download PDF

2. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme

Author

Oporto Espuelas, Macarena, Burridge, Saskia, Kirkwood, Amy A., Bonney, Denise, Watts, Kelly, Shenton, Geoff, Jalowiec, Katarzyna A., O’Reilly, Maeve A., Roddie, Claire, Castleton, Anna, Clesham, Katherine, Nicholson, Emma, Alajangi, Rajesh, Prabhu, Shilpa, George, Lindsay, Uttenthal, Ben, Gabelli, Maria, Neill, Lorna, Besley, Caroline, Chaganti, Sridhar, Wynn, Robert F., Bartram, Jack, Chiesa, Robert, Lucchini, Giovanna, Pavasovic, Vesna, Rao, Anupama, Rao, Kanchan, Silva, Juliana, Samarasinghe, Sujith, Vora, Ajay, Clark, Peter, Cummins, Michelle, Marks, David I., Amrolia, Persis, Hough, Rachael, and Ghorashian, Sara

Published
2024
Full Text
View/download PDF

3. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

4. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

Author

Ballen, Karen, Wang, Tao, He, Naya, Knight, Jennifer M., Hong, Sanghee, Frangoul, Haydar, Verdonck, Leo F., Steinberg, Amir, Diaz, Miguel A., LeMaistre, C. Fred, Badawy, Sherif M., Pu, Jeffrey J., Hashem, Hasan, Savani, Bipin, Sharma, Akshay, Lazarus, Hillard M., Abid, Muhammad Bilal, Tay, Jason, Rangarajan, Hemalatha G., Kindwall-Keller, Tamila, Freytes, Cesar O., Beitinjaneh, Amer, Winestone, Lena E., Gergis, Usama, Farhadfar, Nosha, Bhatt, Neel S., Schears, Raquel M., Gómez-Almaguer, David, Aljurf, Mahmoud, Agrawal, Vaibhav, Kuwatsuka, Yachiyo, Seo, Sachiko, Marks, David I., Lehmann, Leslie, Wood, William A., Hashmi, Shahrukh, and Saber, Wael

Published
2024
Full Text
View/download PDF

5. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States

Author

Bhatt, Neel S, Brazauskas, Ruta, Salit, Rachel B, Syrjala, Karen, Bo-Subait, Stephanie, Tecca, Heather, Badawy, Sherif M, Baker, K Scott, Beitinjaneh, Amer, Bejanyan, Nelli, Byrne, Michael, Dias, Ajoy, Farhadfar, Nosha, Freytes, César O, Ganguly, Siddhartha, Hashmi, Shahrukh, Hayashi, Robert J, Hong, Sanghee, Inamoto, Yoshihiro, Jamani, Kareem, Kasow, Kimberly A, Khera, Nandita, Krem, Maxwell M, Lazarus, Hillard M, Lee, Catherine J, Lee, Stephanie, Majhail, Navneet S, Malone, Adriana K, Marks, David I, Mau, Lih-Wen, Mayo, Samantha J, Muffly, Lori S, Nathan, Sunita, Nishihori, Taiga, Page, Kristin M, Preussler, Jaime, Rangarajan, Hemalatha G, Rotz, Seth J, Salooja, Nina, Savani, Bipin N, Schears, Raquel, Schechter-Finkelstein, Tal, Schiller, Gary, Shah, Ami J, Sharma, Akshay, Wang, Trent, Wirk, Baldeep, Battiwalla, Minoo, Schoemans, Hélène, Hamilton, Betty, Buchbinder, David, Phelan, Rachel, and Shaw, Bronwen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Transplantation, Clinical Research, Rehabilitation, Behavioral and Social Science, Quality Education, Female, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Return to Work, Survivors, Transplantation, Homologous, United States, Young Adult, Hematopoietic cell transplantation, Return to work, Quality of life, Young adult, Immunology, Cardiovascular medicine and haematology
Abstract

Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted this study to assess the post-HCT work status of survivors of allogeneic HCT who underwent HCT as YAs and to analyze the patient-, disease-, and HCT-related factors associated with their work status at 1 year post-HCT. Using Center for International Blood and Marrow Transplant Research data, we evaluated the post-HCT work status (full-time, part-time work, unemployed, or medical disability) of 1365 YA HCT survivors who underwent HCT between 2008 and 2015. Percentages of work status categories were reported at 4 time points: 6 months, 1 year, 2 years, and 3 years post-HCT. Percentages of post-HCT work status categories at the 1-year time point were also described in relation to survivors' pre-HCT work status categories. Factors associated with 1-year post-HCT work status (full-time or part-time work) were examined using logistic regression. From 6 months to 3 years post-HCT, the percentage of survivors working full-time increased from 18.3% to 50.7% and the percentage working part-time increased from 6.9% to 10.5%. Of patients in full-time work pre-HCT, 50% were unemployed or on medical disability at 1 year post-HCT. Female sex (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.40 to 0.77), HCT Comorbidity Index score ≥3 (OR, 0.57; 95% CI, 0.39 to 0.82), pre-HCT unemployment (OR, 0.37; 95% CI, 0.24 to 0.56), medical disability (OR, 0.44; 95% CI, 0.28 to 0.70), development of grade III-IV acute graft-versus-host disease (OR, 0.52; 95% CI, 0.34 to 0.80), and relapse within 1 year post-HCT (OR, 0.34; 95% CI, 0.21 to 0.56) were associated with a lower likelihood of employment at 1 year post-HCT. Compared with myeloablative conditioning (MAC) with total body irradiation (TBI), MAC without TBI (OR, 1.71; 95% CI, 1.16 to 2.53) was associated with a greater likelihood of employment at 1 year post-HCT. Graduate school-level education (OR, 2.47; 95% CI, 1.49 to 4.10) was also associated with a greater likelihood of employment at 1 year post-HCT. Although the work status among YA HCT survivors continued to improve over time, a substantial subset became or remained unemployed or on medical disability. These findings underscore the need for effective interventions to support return to work in this population.

Published
2021

6. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

8. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

Author

Stock, Wendy, Martinelli, Giovanni, Stelljes, Matthias, DeAngelo, Daniel J, Gökbuget, Nicola, Advani, Anjali S, O’Brien, Susan, Liedtke, Michaela, Merchant, Akil A, Cassaday, Ryan D, Wang, Tao, Zhang, Hui, Vandendries, Erik, Jabbour, Elias, Marks, David I, and Kantarjian, Hagop M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Pediatric Cancer, Cancer, Rare Diseases, Hematology, Pediatric, Transplantation, Childhood Leukemia, Regenerative Medicine, Pediatric Research Initiative, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Inotuzumab Ozogamicin, Neoplasm, Residual, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, acute lymphoblastic leukemia, efficacy, hematopoietic stem cell transplantation, inotuzumab ozogamicin, Philadelphia chromosome, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundPatients with relapsed/refractory (R/R) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options.MethodsThe efficacy of inotuzumab ozogamicin (InO), a humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin, was evaluated in R/R ALL patients in the phase 1/2 study 1010 (NCT01363297) and open-label, randomized, phase 3 study 1022 (INO-VATE; NCT01564784). This analysis focused specifically on Ph+ R/R ALL patients. In study 1022, Ph+ patients were randomly assigned 1:1 to InO (n = 22) or standard intensive chemotherapy (SC) (n = 27) and 16 Ph+ patients in study 1010 received InO.ResultsIn study 1022, rates of complete remission/complete remission with incomplete hematologic recovery (CR/CRi) and minimal residual disease (MRD) negativity (patients achieving CR/CRi) were higher with InO (CR/CRi = 73%; MRD = 81%) versus SC (CR/CRi = 56%; MRD = 33%). The corresponding rates in study 1010 were 56% (CR/CRi) and 100% (MRD). The hematopoietic stem cell transplantation (HSCT) rate in study 1022 was 41% versus 19% for InO versus SC; however, there was no benefit in overall survival (median OS: 8.7 vs 8.4 months; hazard ratio, 1.17 [95% CI, 0.64-2.14]). The probability of being event-free (progression-free survival) at 12 months was greater with InO versus SC (20.1% vs 4.8%).ConclusionGiven the substantial improvement in responses and rates of HSCT, InO is an important treatment option for patients with R/R Ph+ ALL. Future studies need to consider better characterization of disease characteristics, more sensitive MRD measurements, MRD-directed therapy before HSCT, and potentially combination therapies, including tyrosine kinase inhibitors.

Published
2021

9. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

10. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Published
2020

11. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries

Author

Zinter, Matt S, Logan, Brent R, Fretham, Caitrin, Sapru, Anil, Abraham, Allistair, Aljurf, Mahmoud D, Arnold, Staci D, Artz, Andrew, Auletta, Jeffery J, Chhabra, Saurabh, Copelan, Edward, Duncan, Christine, Gale, Robert P, Guinan, Eva, Hematti, Peiman, Keating, Amy K, Marks, David I, Olsson, Richard, Savani, Bipin N, Ustun, Celalettin, Williams, Kirsten M, Pasquini, Marcelo C, and Dvorak, Christopher C

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Patient Safety, Clinical Research, Pediatric, Rare Diseases, Cancer, Hematology, Transplantation, Good Health and Well Being, Child, Critical Illness, Hematopoietic Stem Cell Transplantation, Humans, Infant, Intensive Care Units, Pediatric, Registries, Retrospective Studies, Risk Factors, Intensive care units, Hematopoietic stem cell transplantation, Organ dysfunction scores, Prognosis, Survival analysis, Immunology, Cardiovascular medicine and haematology
Abstract

Critically ill pediatric allogeneic hematopoietic cell transplant (HCT) patients may benefit from early and aggressive interventions aimed at reversing the progression of multiorgan dysfunction. Therefore, we evaluated 25 early risk factors for pediatric intensive care unit (PICU) mortality to improve mortality prognostication. We merged the Virtual Pediatric Systems and Center for International Blood and Marrow Transplant Research databases and analyzed 936 critically ill patients ≤21 years of age who had undergone allogeneic HCT and subsequently required PICU admission between January 1, 2009, and December 31, 2014. Of 1532 PICU admissions, the overall PICU mortality rate was 17.4% (95% confidence interval [CI], 15.6% to 19.4%) but was significantly higher for patients requiring mechanical ventilation (44.0%), renal replacement therapy (56.1%), or extracorporeal life support (77.8%). Mortality estimates increased significantly the longer that patients remained in the PICU. Of 25 HCT- and PICU-specific characteristics available at or near the time of PICU admission, moderate/severe pre-HCT renal injury, pre-HCT recipient cytomegalovirus seropositivity,

Published
2020

12. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

Author

DeAngelo, Daniel J, Advani, Anjali S, Marks, David I, Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, Jabbour, Elias, Merchant, Akil, Wang, Tao, Vandendries, Erik, Neuhof, Alexander, Kantarjian, Hagop, and O’Brien, Susan

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Hematology, Childhood Leukemia, Transplantation, Orphan Drug, Rare Diseases, Cancer, Pediatric Research Initiative, Clinical Research, Pediatric, Pediatric Cancer, Good Health and Well Being, Acute Disease, Adult, Antineoplastic Agents, Immunological, Bone Marrow, Humans, Inotuzumab Ozogamicin, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Treatment Outcome, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R ALL patients with low, moderate, or high disease burden, respectively, defined as bone marrow blasts (BMB) 90% (n = 30 vs. 30). Patients in the InO vs. SC arm with low, moderate, and high BMB%, respectively, had improved rates of complete remission/complete remission with incomplete hematologic recovery (74% vs. 46% [p = 0.0022], 75 vs. 27% [p

Published
2020

13. Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia

Author

Patel, Bela, primary, Kirkwood, Amy A., additional, Rowntree, Clare J., additional, Alapi, Krisztina Z., additional, Barretta, Emilio, additional, Clifton‐Hadley, Laura, additional, Creasey, Tom, additional, Lee, SooWah, additional, Marks, David I., additional, Moorman, Anthony V., additional, Morley, Nicholas, additional, Patrick, Pip, additional, Rana, Zaynab, additional, Rijneveld, Anita, additional, Snowden, John A., additional, and Fielding, Adele K., additional

Published
2024
Full Text
View/download PDF

14. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

Author

Marks, David I, Kirkwood, Amy A, Rowntree, Clare J, Aguiar, Melanie, Bailey, Katharine E, Beaton, Brendan, Cahalin, Paul, Castleton, Anna Z, Clifton-Hadley, Laura, Copland, Mhairi, Goldstone, Anthony H, Kelly, Richard, Lawrie, Emma, Lee, SooWah, McMillan, Andrew K, McMullin, Mary Frances, Menne, Tobias F, Mitchell, Rachel J, Moorman, Anthony V, Patel, Bela, Patrick, Pip, Smith, Paul, Taussig, David, Yallop, Deborah, Alapi, Krisztina Zuborne, and Fielding, Adele K

Published
2022
Full Text
View/download PDF

15. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial

Author

Marks, David I, Clifton-Hadley, Laura, Copland, Mhairi, Hussain, Jiaull, Menne, Tobias F, McMillan, Andrew, Moorman, Anthony V, Morley, Nicholas, Okasha, Dina, Patel, Bela, Patrick, Pip, Potter, Michael N, Rowntree, Clare J, Kirkwood, Amy A, and Fielding, Adele K

Published
2022
Full Text
View/download PDF

16. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

Author

Moorman, Anthony V., Barretta, Emilio, Butler, Ellie R., Ward, Eleanor J., Twentyman, Katie, Kirkwood, Amy A., Enshaei, Amir, Schwab, Claire, Creasey, Tom, Leongamornlert, Daniel, Papaemmanuil, Elli, Patrick, Pip, Clifton-Hadley, Laura, Patel, Bela, Menne, Tobias, McMillan, Andrew K., Harrison, Christine J., Rowntree, Clare J., Marks, David I., and Fielding, Adele K.

Published
2022
Full Text
View/download PDF

17. Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation

Author

Bejanyan, Nelli, Zhang, Mei-Jie, Wang, Hai-Lin, Lazaryan, Aleksandr, de Lima, Marcos, Marks, David I, Sandmaier, Brenda M, Bachanova, Veronika, Rowe, Jacob, Tallman, Martin, Kebriaei, Partow, Kharfan-Dabaja, Mohamed, Gale, Robert Peter, Lazarus, Hillard M, Ustun, Celalettin, Copelan, Edward, Hamilton, Betty Ky, Schiller, Gary, Hogan, William, Hashmi, Shahrukh, Seftel, Matthew, Kanakry, Christopher G, Olsson, Richard F, Martino, Rodrigo, Saber, Wael, Khoury, H Jean, and Weisdorf, Daniel J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Hematology, Cancer, Transplantation, Clinical Trials and Supportive Activities, Stem Cell Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Consolidation Chemotherapy, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Myeloablative Agonists, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Survival Analysis, Time Factors, Transplantation, Homologous, Treatment Outcome, Young Adult, ALL, Consolidation chemotherapy, Myeloablative.conditioning, Allogeneic transplant, Myeloablative conditioning, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving ≥2, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values >.40). Multivariable analysis confirmed that consolidation was not prognostic for LFS (relative risk, 1.20, 95% confidence interval, .86 to 1.67; P = .28 for no consolidation; RR, 1.18, 95% confidence interval, .79 to 1.76; P = .41 for 1 cycle versus ≥2 cycles = reference). Similarly, consolidation was not associated with OS, relapse, TRM, or graft-versus-host disease. We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.

Published
2018

18. Practice guideline: Preparation for CAR T‐cell therapy in children and young adults with B‐acute lymphoblastic leukaemia

Author

Mishra, Avijeet Kumar, primary, Burridge, Saskia, additional, Espuelas, Macarena Oporto, additional, O'Reilly, Maeve, additional, Cummins, Michelle, additional, Nicholson, Emma, additional, Wheldon, Sophie, additional, Bonney, Denise, additional, Shenton, Geoff, additional, Marks, David I., additional, Amrolia, Persis J., additional, Hough, Rachael, additional, and Ghorashian, Sara, additional

Published
2024
Full Text
View/download PDF

19. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

Author

Gökbuget, Nicola, primary, Boissel, Nicolas, additional, Chiaretti, Sabina, additional, Dombret, Herve, additional, Doubek, Michael, additional, Fielding, Adele K, additional, Foà, Robin, additional, Giebel, Sebastian, additional, Hoelzer, Dieter, additional, Hunault, Mathilde, additional, Marks, David I, additional, Martinelli, Giovanni, additional, Ottmann, Oliver, additional, Rijneveld, Anita W., additional, Rousselot, Philippe, additional, Ribera, Josep-Maria, additional, and Bassan, Renato, additional

Published
2024
Full Text
View/download PDF

20. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

Author

Gökbuget, Nicola, primary, Boissel, Nicolas, additional, Chiaretti, Sabina, additional, Dombret, Herve, additional, Doubek, Michael, additional, Fielding, Adele K, additional, Foà, Robin, additional, Giebel, Sebastian, additional, Hoelzer, Dieter, additional, Hunault, Mathilde, additional, Marks, David I, additional, Martinelli, Giovanni, additional, Ottmann, Oliver G, additional, Rijneveld, Anita W., additional, Rousselot, Philippe, additional, Ribera, Josep-Maria, additional, and Bassan, Renato, additional

Published
2024
Full Text
View/download PDF

21. IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial

Author

Mitchell, Rachel J., Kirkwood, Amy A., Barretta, Emilio, Clifton-Hadley, Laura, Lawrie, Emma, Lee, SooWah, Leongamornlert, Daniel, Marks, David I., McMillan, Andrew K., Menne, Tobias F., Papaemmanuil, Elli, Patel, Bela, Patrick, Pip, Rowntree, Clare J., Zareian, Nahid, Alapi, Krisztina Zuborne, Moorman, Anthony V., and Fielding, Adele K.

Published
2021
Full Text
View/download PDF

22. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Author

Farhadfar, Nosha, Dias, Ajoy, Wang, Tao, Fretham, Caitrin, Chhabra, Saurabh, Murthy, Hemant S., Broglie, Larisa, D'Souza, Anita, Gadalla, Shahinaz M., Gale, Robert Peter, Hashmi, Shahrukh, Al-Homsi, A. Samer, Hildebrandt, Gerhard C., Hematti, Peiman, Rizzieri, David, Chee, Lynette, Lazarus, Hillard M., Bredeson, Christopher, Jaimes, Edgar A., Beitinjaneh, Amer, Bashey, Asad, Prestidge, Tim, Krem, Maxwell M., Marks, David I., Benoit, Stefanie, Yared, Jean A., Nishihori, Taiga, Olsson, Richard F., Freytes, Cesar O., Stadtmauer, Edward, Savani, Bipin N., Sorror, Mohamed L., Ganguly, Siddhartha, Wingard, John R., and Pasquini, Marcelo

Published
2021
Full Text
View/download PDF

25. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis

Author

Arnold, Staci D., Brazauskas, Ruta, He, Naya, Li, Yimei, Hall, Matt, Atsuta, Yoshiko, Dalal, Jignesh, Hahn, Theresa, Khera, Nandita, Bonfim, Carmem, Hashmi, Shahrukh, Parsons, Susan, Wood, William A., Steinberg, Amir, Freytes, César O., Dandoy, Christopher E., Marks, David I., Lazarus, Hillard M., Abdel-Azim, Hisham, Bitan, Menachem, Diaz, Miguel Angel, Olsson, Richard F., Gergis, Usama, Seber, Adriana, Wirk, Baldeep, LeMaistre, C. Fred, Ustun, Celalettin, Duncan, Christine, Rizzieri, David, Szwajcer, David, Fagioli, Franca, Frangoul, Haydar, Knight, Jennifer M., Kamble, Rammurti T., Mehta, Paulette, Schears, Raquel, Satwani, Prakash, Pulsipher, Michael A., Aplenc, Richard, and Saber, Wael

Published
2020
Full Text
View/download PDF

26. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

27. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy

Author

Kanate, Abraham S., Majhail, Navneet S., Savani, Bipin N., Bredeson, Christopher, Champlin, Richard E., Crawford, Stephen, Giralt, Sergio A., LeMaistre, Charles F., Marks, David I., Omel, James L., Orchard, Paul J., Palmer, Jeanne, Saber, Wael, Veys, Paul A., Carpenter, Paul A., and Hamadani, Mehdi

Published
2020
Full Text
View/download PDF

28. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

30. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

Author

Buchbinder, David, Brazauskas, Ruta, Bo-Subait, Khalid, Ballen, Karen, Parsons, Susan, John, Tami, Hahn, Theresa, Sharma, Akshay, Steinberg, Amir, D'Souza, Anita, Kumar, Anita J., Yoshimi, Ayami, Wirk, Baldeep, Shaw, Bronwen, Freytes, César, LeMaistre, Charles, Bredeson, Christopher, Dandoy, Christopher, Almaguer, David, Marks, David I., Szwajcer, David, Hale, Gregory, Schouten, Harry, Hashem, Hasan, Schoemans, Hélène, Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Tay, Jason, Yared, Jean A., Adekola, Kehinde, Schultz, Kirk R., Lehmann, Leslie, Burns, Linda, Aljurf, Mahmoud, Diaz, Miguel Angel, Majhail, Navneet, Farhadfar, Nosha, Kamble, Rammurti, Olsson, Richard, Schears, Raquel, Seo, Sachiko, Beattie, Sara, Chhabra, Saurabh, Savani, Bipin N., Badawy, Sherif, Ganguly, Siddhartha, Ciurea, Stefan, Marino, Susana, Gergis, Usama, Kuwatsuka, Yachiyo, Inamoto, Yoshihiro, Khera, Nandita, Hashmi, Shahrukh, Wood, William, and Saber, Wael

Published
2020
Full Text
View/download PDF

31. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries

Author

Zinter, Matt S., Logan, Brent R., Fretham, Caitrin, Sapru, Anil, Abraham, Allistair, Aljurf, Mahmoud D., Arnold, Staci D., Artz, Andrew, Auletta, Jeffery J., Chhabra, Saurabh, Copelan, Edward, Duncan, Christine, Gale, Robert P., Guinan, Eva, Hematti, Peiman, Keating, Amy K., Marks, David I., Olsson, Richard, Savani, Bipin N., Ustun, Celalettin, Williams, Kirsten M., Pasquini, Marcelo C., and Dvorak, Christopher C.

Published
2020
Full Text
View/download PDF

32. Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation

Author

Ballen, Karen, Ahn, Kwang Woo, Chen, Min, Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Antin, Joseph, Bhatt, Ami S, Boeckh, Michael, Chen, George, Dandoy, Christopher, George, Biju, Laughlin, Mary J, Lazarus, Hillard M, MacMillan, Margaret L, Margolis, David A, Marks, David I, Norkin, Maxim, Rosenthal, Joseph, Saad, Ayman, Savani, Bipin, Schouten, Harry C, Storek, Jan, Szabolcs, Paul, Ustun, Celalettin, Verneris, Michael R, Waller, Edmund K, Weisdorf, Daniel J, Williams, Kirsten M, Wingard, John R, Wirk, Baldeep, Wolfs, Tom, Young, Jo-Anne H, Auletta, Jeffrey, Komanduri, Krishna V, Lindemans, Caroline, and Riches, Marcie L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Stem Cell Research, Infectious Diseases, Clinical Research, Regenerative Medicine, Transplantation, Hematology, Stem Cell Research - Nonembryonic - Human, 2.2 Factors relating to the physical environment, Aetiology, Infection, Good Health and Well Being, Acute Disease, Adolescent, Adult, Aged, Cord Blood Stem Cell Transplantation, Female, Hematopoietic Stem Cell Transplantation, Histocompatibility, Humans, Incidence, Infections, Leukemia, Male, Middle Aged, Retrospective Studies, Survival Analysis, Unrelated Donors, Young Adult, Umbilical cord blood, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Alternative graft sources (umbilical cord blood [UCB], matched unrelated donors [MUD], or mismatched unrelated donors [MMUD]) enable patients without a matched sibling donor to receive potentially curative hematopoietic cell transplantation (HCT). Retrospective studies demonstrate comparable outcomes among different graft sources. However, the risk and types of infections have not been compared among graft sources. Such information may influence the choice of a particular graft source. We compared the incidence of bacterial, viral, and fungal infections in 1781 adults with acute leukemia who received alternative donor HCT (UCB, n= 568; MUD, n = 930; MMUD, n = 283) between 2008 and 2011. The incidences of bacterial infection at 1 year were 72%, 59%, and 65% (P

Published
2016

33. New Cancers after Autotransplantations for Multiple Myeloma

Author

Mahindra, Anuj, Raval, Girindra, Mehta, Paulette, Brazauskas, Ruta, Zhang, Mei-Jie, Zhong, Xiaobo, Bird, Jennifer M, Freytes, César O, Hale, Gregory A, Herzig, Roger, Holmberg, Leona A, Kamble, Rammurti T, Kumar, Shaji, Lazarus, Hillard M, Majhail, Navneet S, Marks, David I, Moreb, Jan S, Olsson, Richard, Saber, Wael, Savani, Bipin N, Schiller, Gary J, Tay, Jason, Vogl, Dan T, Waller, Edmund K, Wiernik, Peter H, Wirk, Baldeep, Lonial, Sagar, Krishnan, Amrita Y, Dispenzieri, Angela, Brandenburg, Nancy A, Gale, Robert Peter, and Hari, Parameswaran N

Subjects
Cancer, Rare Diseases, Clinical Research, Hematology, Adolescent, Autografts, Child, Child, Preschool, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Multiple Myeloma, Neoplasms, Second Primary, Retrospective Studies, Risk Factors, Sex Factors, Stem Cell Transplantation, United States, Myeloma, Second cancer, Transplantation, Clinical Sciences, Immunology
Abstract

We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7 years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P = .0004), and 3.58 (99% CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.

Published
2015

34. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Author

Hamilton, Betty K., Liu, Ying, Hemmer, Michael T., Majhail, Navneet, Ringden, Olle, Kim, Dennis, Costa, Luciano, Stuart, Robert, Alousi, Amin, Pidala, Joseph A., Couriel, Daniel R., Aljurf, Mahmoud, Antin, Joseph H., Bredeson, Christopher, Cahn, Jean-Yves, Cairo, Mitchell, Choi, Sung Won, Dandoy, Christopher, Gale, Robert Peter, Gergis, Usama, Hematti, Peiman, Inamoto, Yoshihiro, Kamble, Rammurti T., MacMillan, Margaret, Marks, David I., Nemecek, Eneida, Nishihori, Taiga, Saad, Ayman, Savani, Bipin N., Schriber, Jeff, Seo, Sachiko, Socié, Gérard, Teshima, Takanori, Verdonck, Leo F., Waller, Edmund K., Wirk, Mona, Spellman, Stephen R., Arora, Mukta, and Chhabra, Saurabh

Published
2019
Full Text
View/download PDF

35. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation

Author

Saad, Ayman, Lamb, Lawrence, Wang, Tao, Hemmer, Michael T., Spellman, Stephen, Couriel, Daniel, Alousi, Amin, Pidala, Joseph, Abdel-Azim, Hisham, Agrawal, Vaibhav, Aljurf, Mahmoud, Beitinjaneh, Amer M., Bhatt, Vijaya Raj, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Chhabra, Saurabh, Diaz, Miguel Angel, Farhan, Shatha, Floisand, Yngvar, Frangoul, Hadar A., Gadalla, Shahinaz M., Gajewski, James, Gale, Robert Peter, Gandhi, Manish, Gergis, Usama, Hamilton, Betty Ky, Hematti, Peiman, Hildebrandt, Gerhard C., Kamble, Rammurti T., Kanate, Abraham S., Khandelwal, Pooja, Lazaryan, Aleksandr, MacMillan, Margaret, Marks, David I., Martino, Rodrigo, Mehta, Parinda A., Nishihori, Taiga, Olsson, Richard F., Patel, Sagar S., Qayed, Muna, Rangarajan, Hemalatha G., Reshef, Ran, Ringden, Olle, Savani, Bipin N., Schouten, Harry C., Schultz, Kirk R., Seo, Sachiko, Shaffer, Brian C., Solh, Melhem, Teshima, Takanori, Urbano-Ispizua, Alvaro, Verdonck, Leo F., Vij, Ravi, Waller, Edmund K., William, Basem, Wirk, Baldeep, Yared, Jean A., Yu, Lolie C., Arora, Mukta, and Hashmi, Shahrukh

Published
2019
Full Text
View/download PDF

37. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning

Author

McCune, Jeannine S., Wang, Tao, Bo-Subait, Khalid, Aljurf, Mahmoud, Beitinjaneh, Amer, Bubalo, Joseph, Cahn, Jean-Yves, Cerny, Jan, Chhabra, Saurabh, Cumpston, Aaron, Dupuis, L. Lee, Lazarus, Hillard M., Marks, David I., Maziarz, Richard T., Norkin, Maxim, Prestidge, Tim, Mineishi, Shin, Krem, Maxwell M., Pasquini, Marcelo, and Martin, Paul J.

Published
2019
Full Text
View/download PDF

38. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Author

Radivoyevitch, Tomas, Dean, Robert M., Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Molenaar, Remco J., Battiwalla, Minoo, Savani, Bipin N., Flowers, Mary E.D., Cooke, Kenneth R., Hamilton, Betty K., Kalaycio, Matt, Maciejewski, Jaroslaw P., Ahmed, Ibrahim, Akpek, Görgün, Bajel, Ashish, Buchbinder, David, Cahn, Jean-Yves, D’Souza, Anita, Daly, Andrew, DeFilipp, Zachariah, Ganguly, Siddhartha, Hamadani, Mehdi, Hayashi, Robert J., Hematti, Peiman, Inamoto, Yoshihiro, Khera, Nandita, Kindwall-Keller, Tamila, Landau, Heather, Lazarus, Hillard, Majhail, Navneet S., Marks, David I., Olsson, Richard F., Seo, Sachiko, Steinberg, Amir, William, Basem M., Wirk, Baldeep, Yared, Jean A., Aljurf, Mahmoud, Abidi, Muneer H., Allewelt, Heather, Beitinjaneh, Amer, Cook, Rachel, Cornell, Robert F., Fay, Joseph W., Hale, Gregory, Chakrabarty, Jennifer Holter, Jodele, Sonata, Kasow, Kimberly A., Mahindra, Anuj, Malone, Adriana K., Popat, Uday, Rizzo, J. Douglas, Schouten, Harry C., Warwick, Anne B., Wood, William A., Sekeres, Mikkael A., Litzow, Mark R., Gale, Robert P., and Hashmi, Shahrukh K.

Published
2018
Full Text
View/download PDF

39. POSTER: ALL-471 Veno-Occlusive Disease Risk and Other Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin and Proceeding to Hematopoietic Stem Cell Transplantation

Author

de Lima, Marcos, primary, Kebriaei, Partow, additional, Lanza, Francesco, additional, Cho, Christina, additional, Popradi, Gizelle, additional, Kaur, Manmeet, additional, Zhang, Mei-Jie, additional, Zhang, Fan, additional, Shah, Richa, additional, Vandendries, Erik, additional, Asomaning, Kofi, additional, Dorman, Stephanie, additional, Stelljes, Matthias, additional, Marks, David I., additional, and Saber, Wael, additional

Published
2023
Full Text
View/download PDF

40. ALL-471 Veno-Occlusive Disease Risk and Other Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin and Proceeding to Hematopoietic Stem Cell Transplantation

Author

de Lima, Marcos, primary, Kebriaei, Partow, additional, Lanza, Francesco, additional, Cho, Christina, additional, Popradi, Gizelle, additional, Kaur, Manmeet, additional, Zhang, Mei-Jie, additional, Zhang, Fan, additional, Shah, Richa, additional, Vandendries, Erik, additional, Asomaning, Kofi, additional, Dorman, Stephanie, additional, Stelljes, Matthias, additional, Marks, David I., additional, and Saber, Wael, additional

Published
2023
Full Text
View/download PDF

41. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

42. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis

Author

Qayed, Muna, Wang, Tao, Hemmer, Michael T., Spellman, Stephen, Arora, Mukta, Couriel, Daniel, Alousi, Amin, Pidala, Joseph, Abdel-Azim, Hisham, Aljurf, Mahmoud, Ayas, Mouhab, Bitan, Menachem, Cairo, Mitchell, Choi, Sung Won, Dandoy, Christopher, Delgado, David, Gale, Robert Peter, Hale, Gregory, Frangoul, Haydar, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Lehman, Leslie, Levine, John, MacMillan, Margaret, Marks, David I., Nishihori, Taiga, Olsson, Richard F., Hematti, Peiman, Ringden, Olov, Saad, Ayman, Satwani, Prakash, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Shenoy, Shalini, Waller, Edmund K., Yu, Lolie, Horowitz, Mary M., and Horan, John

Published
2018
Full Text
View/download PDF

43. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Giebel, Sebastian, Marks, David I., Boissel, Nicolas, Baron, Frederic, Chiaretti, Sabina, Ciceri, Fabio, Cornelissen, Jan J., Doubek, Michael, Esteve, Jordi, Fielding, Adele, Foa, Robin, Gorin, Norbert-Claude, Gökbuget, Nicola, Hallböök, Helene, Hoelzer, Dieter, Paravichnikova, Elena, Ribera, Josep-Maria, Savani, Bipin, Rijneveld, Anita W., Schmid, Christoph, Wartiovaara-Kautto, Ulla, Mohty, Mohamad, Nagler, Arnon, and Dombret, Hervé

Published
2019
Full Text
View/download PDF

44. ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission

Author

Marks, David I, primary, Castleton, Anna, additional, Olavarria, Eduardo, additional, Gilleece, Maria, additional, Fielding, Adele, additional, Mikhaeel, George, additional, Beasley, Matthew, additional, Diez, Patricia, additional, Jackson, Aimee, additional, Hodgkinson, Andrea, additional, Elhanied, Mohamed, additional, and Chakraverty, Ronjon, additional

Published
2023
Full Text
View/download PDF

45. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age

Author

Vrooman, Lynda M., Millard, Heather R., Brazauskas, Ruta, Majhail, Navneet S., Battiwalla, Minoo, Flowers, Mary E., Savani, Bipin N., Akpek, Görgün, Aljurf, Mahmoud, Bajwa, Rajinder, Baker, K. Scott, Beitinjaneh, Amer, Bitan, Menachem, Buchbinder, David, Chow, Eric, Dandoy, Christopher, Dietz, Andrew C., Diller, Lisa, Gale, Robert Peter, Hashmi, Shahrukh K., Hayashi, Robert J., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberly A., Kletzel, Morris, Lazarus, Hillard M., Malone, Adriana K., Marks, David I., O'Brien, Tracey A., Olsson, Richard F., Ringden, Olle, Seo, Sachiko, Steinberg, Amir, Yu, Lolie C., Warwick, Anne, Shaw, Bronwen, and Duncan, Christine

Published
2017
Full Text
View/download PDF

46. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Author

Kantarjian, Hagop M, DeAngelo, Daniel J, Advani, Anjali S, Stelljes, Matthias, Kebriaei, Partow, Cassaday, Ryan D, Merchant, Akil A, Fujishima, Naohito, Uchida, Toshiki, Calbacho, Maria, Ejduk, Anna A, O'Brien, Susan M, Jabbour, Elias J, Zhang, Hui, Sleight, Barbara J, Vandendries, Erik R, and Marks, David I

Published
2017
Full Text
View/download PDF

47. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, Betül, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L., Savani, Bipin N., Bredeson, Christopher, Weisdorf, Daniel, Marks, David I., Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C., Hale, Gregory A., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Liesveld, Jane L., Yared, Jean A., Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F., Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R., Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F., Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Published
2021
Full Text
View/download PDF

48. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia

Author

Liu, Hien Duong, Ahn, Kwang Woo, Hu, Zhen-Huan, Hamadani, Mehdi, Nishihori, Taiga, Wirk, Baldeep, Beitinjaneh, Amer, Rizzieri, David, Grunwald, Michael R., Sabloff, Mitchell, Olsson, Richard F., Bajel, Ashish, Bredeson, Christopher, Daly, Andrew, Inamoto, Yoshihiro, Majhail, Navneet, Saad, Ayman, Gupta, Vikas, Gerds, Aaron, Malone, Adriana, Tallman, Martin, Reshef, Ran, Marks, David I., Copelan, Edward, Gergis, Usama, Savoie, Mary Lynn, Ustun, Celalettin, Litzow, Mark R., Cahn, Jean-Yves, Kindwall-Keller, Tamila, Akpek, Gorgun, Savani, Bipin N., Aljurf, Mahmoud, Rowe, Jacob M., Wiernik, Peter H., Hsu, Jack W., Cortes, Jorge, Kalaycio, Matt, Maziarz, Richard, Sobecks, Ronald, Popat, Uday, Alyea, Edwin, and Saber, Wael

Published
2017
Full Text
View/download PDF

50. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results